Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents
- 1 September 1989
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 3 (5) , 675-682
- https://doi.org/10.1007/bf01857619
Abstract
Class III antiarrhythmic agents may prolong refractoriness via modulation of ion channels, which may be sensitive to Ca2+ regulatory proteins or enzymes. Accordingly, the purpose of this study was to quantitate the effects of several structurally diverse class III antiarrhythmic agents on calmodulin-regulated enzymes and protein kinase C activity, and to evaluate the ability of these agents and known calmodulin antagonists to prolong cardiac refractoriness in vivo. The rank order of potency (IC50;μM) of selected class III antiarrhythmic agents and reference calmodulin antagonists as inhibitors of calmodulin-regulated phosphodiesterase activity were: calmidazolium (0.12 μM)>amiodarone (0.62 μM)>desethylamiodarone (1.5 μM)>trifluoperazine (4.3 μM), bepridil (5 μM)>W-7 (7.5 μM), clofilium (13 μM). Similar concentration-related inhibition was evident in a second calmodulin-regulated system, inhibition of myosin light-chain phosphorylation and superprecipitation light-chain phosphorylation and superprecipitation of arterial actomyosin. Sotalol and tetraethylammonium were inactive at 100 μM. Protein kinase C activity was also inhibited by some of these agents; desethylamiodarone (IC50=11 μM) was more potent than the reference agent, H-7 (IC50=79 μM), or amiodarone (38% inhibition at 100 μM) and clofilium (32% inhibition at 100 μM). In vivo, the minimally effective doses required to increase ventricular effective refractory doses required to increase ventricular effective refractory periods in paced guinea pigs were (in mg/kg) bepridil, sotalol [1]>clofilium [3]>amiodarone [10]>W-7, desethylamiodarone [20]. No changes in refractory period were noted with maximum testable doses of calmidazolium or trifluoperazine. These studies show that some, but not all, class III antiarrhythmic agents are effective and potent calmodulin antagonists or protein kinase C inhibitors. Moreover, some calmodulin antagonists are effective at prolonging refractoriness in vivo. However, a lack of correlation between these agents suggests that these mechanisms are not solely responsible for the prolongation of refractoriness of all class III agents.Keywords
This publication has 26 references indexed in Scilit:
- Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscleEuropean Journal of Pharmacology, 1988
- Slow calcium channel blockers and calmodulinBiochemical Pharmacology, 1985
- Phosphorylation of Ion channelsThe Journal of Membrane Biology, 1985
- Effects of the calmodulin inhibitor, trifluoperazine, on membrane potentials and slow action potentials of cultured heart cellsEuropean Journal of Pharmacology, 1984
- A Classification of Antiarrhythmic Actions Reassessed After a Decade of New DrugsThe Journal of Clinical Pharmacology, 1984
- Phospholipid-sensitive Ca2+-dependent protein kinase inhibition by R-24571, A calmodulin antagonistBiochemical Pharmacology, 1984
- Amiodarone pharmacokineticsAmerican Heart Journal, 1983
- Inhibition of calcium‐activated potassium conductance of human erythrocytes by calmodulin inhibitory drugsFEBS Letters, 1981
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976